Non-Opioid Depressants: Benzos, Z-Drugs, and the Ones You Didn't Know About
Prescribed to calm anxiety and sleep. Capable of producing some of the hardest withdrawals in medicine.
Body — 8 lenses: [Science: GABA-A positive allosteric modulators (benzos, Z-drugs), GHB at GHB receptor + GABA-B. Biology: sedation, anterograde amnesia, paradoxical disinhibition. Withdrawal: kindling effect, protracted symptoms, seizure risk. Psychology: chronic benzo dependence via therapeutic use; iatrogenic pathway; cognitive effects. Policy: Schedule IV (benzos, Z-drugs), II (barbiturates), I (GHB), but designer benzos (etizolam, flubromazolam) circulate as novel psychoactives. Trends: benzo Rx rising; designer benzo detection in overdose deaths; fentanyl-benzo co-use lethal combination. Social: the “mother’s little helper” legacy; TikTok-era anxiety prescribing. Treatment: slow taper (Ashton Manual), CBT for anxiety, flumazenil only for overdose. Harm reduction: NEVER mix with opioids/alcohol, test-strip availability for designer benzos, naloxone doesn’t reverse benzo respiratory depression.]
Sources Cited
- 01.A
- 02.Bhttps://www.benzoinfo.comBenzodiazepine Information Coalition
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Doctors Are Writing Fewer Benzodiazepine Prescriptions. The Counterfeits Are Getting Stronger.
Benzodiazepine dispensing fell 26.7% from 2013 to 2024 while designer benzodiazepines took over lab detections. What a pharmacist's twenty-year dependence, and his withdrawal, say about what is missing in between.
Science & MedicineThree Hundred and Seventy-One Trials Later, There Is Still No Approved Drug for Meth or Cocaine. The Best Treatment We Have Is a Gift Card.
An umbrella review of 371 trials found no approved medication for stimulant use disorder. What that means for people using meth or cocaine, and for the programs that serve them.
Science & MedicineOne Dose Quieted Her Head for Two Hours. Within Weeks She Was Buying More.
A 2026 BJPsych Open case report describes a 25-year-old woman who developed ketamine addiction after one clinical dose. What it shows about relief, dependence and what clinics and clients should ask.